CN103494201A - Osteoarticular disease care product of L-ascorbyl dipalmitate - Google Patents
Osteoarticular disease care product of L-ascorbyl dipalmitate Download PDFInfo
- Publication number
- CN103494201A CN103494201A CN201310489557.1A CN201310489557A CN103494201A CN 103494201 A CN103494201 A CN 103494201A CN 201310489557 A CN201310489557 A CN 201310489557A CN 103494201 A CN103494201 A CN 103494201A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- calcium
- bone
- care product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000011575 calcium Substances 0.000 claims abstract description 44
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 44
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 35
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 8
- 229940067606 lecithin Drugs 0.000 claims abstract description 8
- 235000010445 lecithin Nutrition 0.000 claims abstract description 8
- 239000000787 lecithin Substances 0.000 claims abstract description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000011790 ferrous sulphate Substances 0.000 claims abstract description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 7
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 7
- 235000000193 zinc lactate Nutrition 0.000 claims abstract description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 4
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 4
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 4
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002477 riboflavin Drugs 0.000 claims abstract description 4
- 229960003495 thiamine Drugs 0.000 claims abstract description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 4
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 4
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 4
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- 229940050168 zinc lactate Drugs 0.000 claims abstract description 3
- 239000011576 zinc lactate Substances 0.000 claims abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 19
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 15
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 15
- 229940088594 vitamin Drugs 0.000 claims description 14
- 229930003231 vitamin Natural products 0.000 claims description 14
- 235000013343 vitamin Nutrition 0.000 claims description 14
- 239000011782 vitamin Substances 0.000 claims description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 14
- 208000020084 Bone disease Diseases 0.000 claims description 13
- 208000012659 Joint disease Diseases 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- -1 1.2 parts Chemical compound 0.000 claims description 9
- 150000000998 L-ascorbyl palmitates Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 14
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract 2
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 17
- 229920001436 collagen Polymers 0.000 description 16
- 239000000047 product Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 108010048734 sclerotin Proteins 0.000 description 6
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000019625 fat content Nutrition 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an osteoarticular disease care product of L-ascorbyl dipalmitate. The product is made with, by weight, 38-45 parts of L-ascorbyl dipalmitate, 1.0-1.1 parts of vitamin A, 1.2-1.3 parts of vitamin B1, 1.2-1.3 parts of vitamin B2, 0.1-0.2 part of vitamin B6, 0.001-0.002 part of vitamin B12, 2.2-2.3 parts of vitamin E, 1.2-1.4 parts of zinc lactate, 2.0-2.2 parts of ferrous sulfate, 100-120 parts of chelated calcium, 1.0-1.3 parts of magnesium oxide, and 2.3-2.7 parts of lecithin. The osteoarticular disease care product is a liposoluble substance; nutrients necessary to human bodies are fully considered; the nutrients are reasonably combined; and the product has the effects of discharging bone joint toxin and assisting in promoting ossein generation and calcium absorption.
Description
Technical field
The present invention relates to a kind of health products of bone and joint diseases, relate in particular to a kind of health products of the bone and joint diseases by the Ascorbyl Palmitate compatibility.
Background technology
Bone and joint diseases is a class common disease, up-to-date osteology research surprising discovery: arthralgia, swelling, stiff, powerlessness, screak, the root of the disease such as cartilage wearing and tearing is that ossein is subject to immune fault analysis, calcium deficiency causes absolutely not.Ossein is be present in collagen in human body and animal body a kind of, is human articular cartilage, and epiphyseal cartilage and bone trabecular Main Ingredients and Appearance, have 70%～86% in the bone organic matter, ossein.Ossein is also the important component that forms human muscle, skin, for the toughness, the harmony of human motion and the elasticity of skin that keep bone, has very great help.
Human body self is to a kind of Epstein (EpsteinBarr by name, abbreviation EB) virus has genetic congenital allergy, and the amino acid in the amino acid of this virus and human bone collagen is closely similar, so when the human immune system produces antibody attack Epstein virus, also mistakenly endochondral ossein is attacked to (also claiming " immunological cross-reaction ") as external foreign matter, thereby make cartilage impaired, the lubricity variation; Cartilage surface grows spur, swelling, and interarticular space diminishes, and activity is obstructed, and pain endlessly, if lack treatment, causes bone to break the most at last.Immune problem is only started with and could be solved from immune system.Ossein is through stomach, after the identification of small intestine lymph, make immune system produce " tolerance " identification, through cartilaginous tissue, repair fast cartilage, eliminate joint pain, swelling, stiff, powerlessness, sound, osteoproliferation, spur, frozen shoulder, tennis elbow etc. are arranged, this process is " oral tolerization " (OralTolerization).
Prevention and the simple supplement calcium for the treatment of bone joint problem can not be dealt with problems fully, and the high-absorbility of calcium must assist higher calcium deposition and higher utilization rate just can tackle the problem at its root.Enough calcium intakes and corresponding collagenous fibres are the essential condition of skeletonization, and indispensable, this is also one of key element prevented bone joint problem.Ossein and calcium can increase bone density fully effectively, strengthen elasticity and the toughness of bone, thereby set up and recover good, normal sclerotin, could effectively prevent bone joint problem.When human body is suitable at synthesis rate and the decomposition rate of collagen at an early age, can't produce the problem that collagen lacks, and, after 25 years old, the synthetic collagen speed of human body starts to descend, so collagen starts to produce the problem lacked.Once collagen starts to lack, and may produce metabolism of articular cartilage speed slow, causes mobility poor, slowly forms degenerative arthritis; Sclerotin starts a large amount of losses.
The generation of collagen mainly contains two kinds of approach, the one, the edible food that contains protein, breaks down into amino acids in alimentary canal, then by intestinal absorption, by blood transportation to each cell, then the genetic transcription of the former albumen of nucleus internal control glue becomes mRNA, and mRNA utilizes the just synthetic collagen of amino acid.Macromolecular collagen protein enters after human body and needs to be degraded to small-molecular peptides, amino acid and just can be absorbed by the body, and the real composition effectively absorbed is also few, and the most fat contents of these foods are higher, often is not suitable for edible.The 2nd, the oneself of collagen generates.
The product of this several years collagens is various of a great variety, for oral administration, outer painting is multifarious on the market, supplementary collagen product is all to extract with it from animal, to stomach have stimulation, molecule large, be difficult for absorbing, the long-term use have rejection, easily cause all kinds of skin diseases.
The content of calcium in human body is many, and becoming human body to include the calcium total amount is 1200～2000g, is about 2% left and right of body weight.Calcium in body exists with two kinds of forms: the form with hydroxyapatite together with phosphorus of the calcium 99% or more forms bone salts, be present in bone and tooth, all the other approximately 1% calcium with ionic species, be present in soft tissue, extracellular fluid and blood, be referred to as miscible calcium pool.Above-mentioned two kinds of calcium are keeping dynamic balance state.Calcium in bone constantly discharges from osteoclast, and the calcium ion entered in ，Er Gai pond, calcium pond constantly is deposited in Gegenbaur's cell, forms new bone.
Calcium distribution in vivo is constant but also balance not only, and this life to body is most important.Calcium in human body has following physiological function to comprise: sclerous tissues's compositions such as the bone of formation human body, tooth; Intracellular chemical messenger, the transmission of the cell that affects the nerves, clotting mechanism be unable to do without calcium; Control the necessary triggering agent of fundamental reaction between myosin, actin, ATP; Affect the ion permeability of cell membrane.During calcium deficiency, cause calcium content in body, calcium balance, calcium concentration gradient to change, cause metabolic calcium disorder, cause body to produce many diseases, common as osteoporosis, the fragility that shows as bone increases, height shortening, hunchback, back pain, fracture.
If calcium in diet intake deficiency, or enteron aisle reduces the absorption of calcium, will cause that body bears calcium balance.In order to maintain normal calcium level, body can, by promotion osteolysises such as increase parathyroid hormone secretions, " migrate " in blood the calcium in bone, thereby cause sclerotin to reduce, be i.e. bone loss.This calcium state unable to make ends meet continues for a long time, and sclerotin will become loose porous and be easy to fracture.And calcium supplementing product on the market mainly divides organic calcium and inorganic calcium, the inorganic calcium calcium content is higher, but it is not soluble, need to consume a large amount of hydrochloric acid in gastric juice and make that calcium is free out becomes ionic condition just can be absorbed in human body, intestines and stomach are had to certain spread effect, the organic calcium calcium content, lower than inorganic calcium, often needs to take multiple dose.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of fat-soluble bone and joint diseases health products that promote that ossein generates and calcium absorbs are provided.
To achieve these goals, the technical solution used in the present invention is:
A kind of bone and joint diseases health products of Ascorbyl Palmitate compatibility, made by following raw materials by weight portion: Ascorbyl Palmitate 38-45 part, vitamin A 1.0-1.1 part, vitamin B1 1.2-1.3 part, vitamin B2 1.2-1.3 part, vitamin B6 0.1-0.2 part, cobalamin 0.001-0.002 part, vitamin E 2.2-2.3 part, zinc lactate 1.2-1.4 part, ferrous sulfate 2.0-2.2 part, chelating calcium 100-120 part, magnesia 1.0-1.3 part, lecithin 2.3-2.7 part.
The bone and joint diseases health products of above-mentioned a kind of Ascorbyl Palmitate compatibility, made by following raw materials by weight portion: 42 parts of Ascorbyl Palmitates, 1 part of vitamin A, 1.25 parts of vitamin B1s, 1.25 parts of vitamin B2s, 0.15 part of vitamin B6,0.0015 part of cobalamin, 2.25 parts of vitamin Es, 1.30 parts of zinc lactates, 2.2 parts, ferrous sulfate, 110 parts of chelating calcium, 1.2 parts, magnesia, 2.5 parts, lecithin.
The present invention utilizes amino acid and Ascorbyl Palmitate to rebuild sclerotin, is free from side effects, and can promotes whereby the human growth hormone, and the aging-resistant effect is arranged.The human growth hormone can repair the vital organs of the human body, bone (marrow) itself belongs to blood forming organ, very naturally also at the row of repairing list, therefore utilize this basic principle, utilize Ascorbyl Palmitate to promote the generation of ossein, find the methods for the treatment of to bone and joint diseases had no side effect safely.
Ascorbyl Palmitate is a kind of fatsoluble vitamin C derivative, the destabilizing factor that it can isolation from oxygen causes water-soluble vitamin c, Ascorbyl Palmitate can be fast space between cells by gastrointestinal mucosal directly enter human body cell, dissolve in blood, cell membrane and lipid, due to lysine, proline is small-molecule substance, therefore, lysine and proline, add Ascorbyl Palmitate synthesized human self collagen albumen, provide enough active raw materials for cell simultaneously, improve enzymatic activity, the potential of active cell, start the body ego repair mechanism, make much to can't see clinically the chronic problem of hope, the immunity problem obtains good Regeneration and Repair so that rehabilitation.
Bone metabolism and amino acid have close relationship equally, and lysine is the key element of assisting absorption calcareous in intestines and sclerotin collagen to form, and can suppress again the calcareous of absorption and run off from urine, can strengthen arginic effect.
Vitamin A, vitamin B1, vitamin B2, vitamin B6, cobalamin and vitamin E add the oxidation resistant effect of playing, the destruction of not only reducing the radical pair collagen, can also effectively promote the effectively synthetic of collagen in body.Vitamin A can remote-effects calcium function performance because vitamin A can promote the synthetic and osteocyte of protein differentiation, can promote mucopolysaccharide synthetic, affect the renewal growth of bone tissue.
The absorption of microelement-supplementing.In human body, when magnesium, zinc insufficiency of intake, the activity of osteoclast just can strengthen, and the activity of Gegenbaur's cell is suppressed, and growth rate slows down, and causes into bone disorders.Clinical research shows, the insufficiency of intakes such as magnesium, zinc also can exert an adverse impact to maintaining of bone amount.The calcium that the present invention adopts is that " the mobile calcium storehouse " that chelating calcium forms a kind of mobile buffering in blood, in the place that needs calcium, can slowly discharge calcium ion, can not cause the hypercalcemia disease because of excessive concentration.Trace elements iron is the important component of corpuscular hemoglobin, and hemoglobin takes oxygen in histocyte to, as iron deficiency just can not synthetic hemoglobin, oxygen just can't be carried, histocyte just can not carry out eubolism, adds appropriate iron, improves bioavilability of the present invention.
Lecithin has the function that strengthens the osteocyte function to have certain effect to bone cell growth, thus phosphatide the rear bone of fracturing is got well is also very useful.
The invention belongs to liposoluble substance, take into full account modern needed by human body nutriment, and the environmental change of gene expression, reasonable compatibility nutriment.Effectively improve stomach, possess following effect simultaneously:
(1) stop 36-48 hour in human body, get rid of bone joint toxin;
(2) help and promote self ossein generation;
(3) bioavailability is 10 times of light water dissolubility calcium supplementing product;
(4) swollen, the anti-inflammatory of can dispelling, promote wound healing.
The specific embodiment
The bone and joint diseases health products of 1 one kinds of Ascorbyl Palmitate compatibilities of embodiment
Raw material components: 40 milligrams of Ascorbyl Palmitates, 1 milligram of vitamin A, 1.20 milligrams of vitamin B1s, 1.20 milligrams of vitamin B2s, 0.10 milligram of vitamin B6, cobalamin 1.0 micrograms, 2.25 milligrams of vitamin Es, 1.20 milligrams of zinc lactates, 2.0 milligrams, ferrous sulfate, 100 milligrams of chelating calcium, 1.0 milligrams, magnesia, 2.3 milligrams, lecithin.
The preparation method: above-mentioned each raw material is mixed in proportion, minute encapsulated after dry in, can obtain capsule, the raw material of every seed lac wafer forms as above.
The bone and joint diseases health products of 2 one kinds of Ascorbyl Palmitate compatibilities of embodiment
Raw material components: 42 milligrams of Ascorbyl Palmitates, 1 milligram of vitamin A, 1.25 milligrams of vitamin B1s, 1.25 milligrams of vitamin B2s, 0.15 milligram of vitamin B6, cobalamin 1.5 micrograms, 2.25 milligrams of vitamin Es, 1.30 milligrams of zinc lactates, 2.2 milligrams, ferrous sulfate, 110 milligrams of chelating calcium, 1.2 milligrams, magnesia, 2.5 milligrams, lecithin.
The preparation method: above-mentioned each raw meal is mixed, carry out granulation, dry rear packing, can obtain granule, the raw material of every granule forms as above.
Example 3 effect embodiment
With the particle of example 2, choose at random male 50 people, female 50 people, 65 ~ 75 years old age, for improving the symptoms such as bone joint pain, anchylosis and soreness and weakness of waist and knees, take 4 everyone every day, take 3 months, total effective rate 92%, concrete condition is as follows:
1) recovery from illness: recover 45 people after treatment.
2) produce effects: through treatment posterior joint pain, obviously alleviate, anchylosis obviously alleviates, and soreness and weakness of waist and knees obviously reduces, and the bone density index is obviously recovered, and immunity strengthens 15 people.
3) take a turn for the better: through treatment posterior joint pain, alleviate a little, anchylosis alleviates a little, and soreness and weakness of waist and knees reduces a little, and the bone density index is recovered a little, and immunity strengthens 32 people a little.
4) invalid: through treatment posterior joint pain, do not alleviate, anchylosis does not alleviate, and soreness and weakness of waist and knees does not reduce, and the bone density index is not recovered, and immunity does not strengthen 8 people.
Claims (2)
1. the bone and joint diseases health products of an Ascorbyl Palmitate compatibility, is characterized in that: by following raw materials by weight portion, made: Ascorbyl Palmitate 38-45 part, vitamin A 1.0-1.1 part, vitamin B1 1.2-1.3 part, vitamin B2 1.2-1.3 part, vitamin B6 0.1-0.2 part, cobalamin 0.001-0.002 part, vitamin E 2.2-2.3 part, zinc lactate 1.2-1.4 part, ferrous sulfate 2.0-2.2 part, chelating calcium 100-120 part, magnesia 1.0-1.3 part, lecithin 2.3-2.7 part.
2. the bone and joint diseases health products of a kind of Ascorbyl Palmitate compatibility as claimed in claim 1, is characterized in that: by following raw materials by weight portion, made: 42 parts of Ascorbyl Palmitates, 1 part of vitamin A, 1.25 parts of vitamin B1s, 1.25 parts of vitamin B2s, 0.15 part of vitamin B6,0.0015 part of cobalamin, 2.25 parts of vitamin Es, 1.30 parts of zinc lactates, 2.2 parts, ferrous sulfate, 110 parts of chelating calcium, 1.2 parts, magnesia, 2.5 parts, lecithin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310489557.1A CN103494201B (en) | 2013-10-18 | 2013-10-18 | Osteoarticular disease care product of L-ascorbyl dipalmitate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310489557.1A CN103494201B (en) | 2013-10-18 | 2013-10-18 | Osteoarticular disease care product of L-ascorbyl dipalmitate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103494201A true CN103494201A (en) | 2014-01-08 |
| CN103494201B CN103494201B (en) | 2015-03-11 |
Family
ID=49859540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310489557.1A Active CN103494201B (en) | 2013-10-18 | 2013-10-18 | Osteoarticular disease care product of L-ascorbyl dipalmitate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494201B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113100251A (en) * | 2021-04-25 | 2021-07-13 | 渭南东旺农华生物科技有限公司 | Agricultural composition containing lecithin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20310493U1 (en) * | 2003-07-08 | 2003-10-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Micronutrient combination product for dietetic treatment of inflammatory-rheumatic diseases and osteoporosis, containing specific amounts of several vitamins, minerals, trace elements and antioxidants |
| CN1500523A (en) * | 2002-11-18 | 2004-06-02 | 上海医药工业研究院 | Protein preparation for enhancing sclerotin and its preparation method |
| CN101720928A (en) * | 2008-10-27 | 2010-06-09 | 柯宏 | Combination for preventing and curing degenerative disease of bone and joint |
| CN103083621A (en) * | 2013-02-07 | 2013-05-08 | 涂雪莲 | Medical composition for treating osteoarthritis |
-
2013
- 2013-10-18 CN CN201310489557.1A patent/CN103494201B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500523A (en) * | 2002-11-18 | 2004-06-02 | 上海医药工业研究院 | Protein preparation for enhancing sclerotin and its preparation method |
| DE20310493U1 (en) * | 2003-07-08 | 2003-10-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Micronutrient combination product for dietetic treatment of inflammatory-rheumatic diseases and osteoporosis, containing specific amounts of several vitamins, minerals, trace elements and antioxidants |
| CN101720928A (en) * | 2008-10-27 | 2010-06-09 | 柯宏 | Combination for preventing and curing degenerative disease of bone and joint |
| CN103083621A (en) * | 2013-02-07 | 2013-05-08 | 涂雪莲 | Medical composition for treating osteoarthritis |
Non-Patent Citations (1)
| Title |
|---|
| 梁春辉，等: "胶原多肽螯合钙壮骨作用研究", 《河北农业大学学报》, vol. 33, no. 5, 30 September 2010 (2010-09-30), pages 94 - 97 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113100251A (en) * | 2021-04-25 | 2021-07-13 | 渭南东旺农华生物科技有限公司 | Agricultural composition containing lecithin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103494201B (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| EP2730286B1 (en) | Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints | |
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| MX2015005649A (en) | Collagen hydrolyzate and use thereof. | |
| CN101695382A (en) | Calcium supplementing preparation with functions of improving bones and joints | |
| CN1961957A (en) | Anti-aging colon absorption preparation | |
| CN101537174A (en) | Health preserving calcium | |
| CN107375221A (en) | One kind contains farnoquinone calcium tablet and preparation method thereof | |
| CN107373450B (en) | A kind of ultra micro high calcium deep-sea collagen powder and its preparation method and application | |
| CN108456248A (en) | Hydrolyze jellyfish I types, II types and collagen type v albumen and application thereof | |
| CN107616507A (en) | A kind of ocean polypeptide spy's dietary seafood for chornic arthritis edible for patients | |
| CN114557448A (en) | Preparation easy to be absorbed by human body and capable of improving human cartilage tissue and preparation method | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| CN101703759A (en) | Lecithin high-calcium capsules and production process thereof | |
| CN101455396A (en) | Nutrient health-care food capable of promoting bone and bone arthrosis health | |
| CN103494201B (en) | Osteoarticular disease care product of L-ascorbyl dipalmitate | |
| CN101268836B (en) | Nutrition high calcium medicinal granule and preparing technique | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| CN102091324A (en) | Calcium for nourishing bones | |
| CN103238839A (en) | Food composition containing collagen used for maintaining joints | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| CN105831738A (en) | Polypeptide glucosamine chondroitin nutritional health food | |
| CN105010933A (en) | Compound nutrition product with liver injury repairing effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190201 Address after: 116620 19-3-2-2 ShuangD4 Street, Dalian Economic and Technological Development Zone, Liaoning Province Patentee after: One bio engineering technology (Dalian) Co., Ltd. Address before: 116620 Unit 19-3, ShuangD Port, ShuangD Fourth Street, Jinzhou New District, Dalian City, Liaoning Province Patentee before: Dalian 5 land 78 bioengineering Co., Ltds |
|
| TR01 | Transfer of patent right |